Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Mucosal Melanoma | Research

Development and validation of a nomogram for predicting overall survival in patients with sinonasal mucosal melanoma

Authors: Zhenzhen Zhu, Weiqing Wang, Yang Zha, Xiaowei Wang, Surita Aodeng, Lei Wang, Yuzhuo Liu, Wei Lv

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Sinonasal mucosal melanoma (SNMM) is a relatively rare malignant tumour with a poor prognosis. This study was designed to identify prognostic factors and establish a nomogram model to predict the overall survival (OS) of patients with SNMM.

Methods

A total of 459 patients with SNMM were selected from the Surveillance, Epidemiology, and End Results (SEER) database as the training cohort. Univariate and multivariate Cox regression analyses were used to screen for independent factors associated with patient prognosis and develop the nomogram model. In addition, external validation was performed to evaluate the effectiveness of the nomogram with a cohort of 34 patients with SNMM from Peking Union Medical College Hospital.

Results

The median OS in the cohort from the SEER database was 28 months. The 1-year, 3-year and 5-year OS rates were 69.8%, 40.4%, and 30.0%, respectively. Multivariate Cox regression analysis indicated that age, T stage, N stage, surgery and radiotherapy were independent variables associated with OS. The areas under the receiver operating characteristic curves (AUCs) of the nomograms for predicting 1-, 3- and 5-year OS were 0.78, 0.71 and 0.71, respectively, in the training cohort. In the validation cohort, the area under the curve (AUC) of the nomogram for predicting 1-, 3- and 5-year OS were 0.90, 0.75 and 0.78, respectively. Patients were classified into low- and high-risk groups based on the total score of the nomogram. Patients in the low-risk group had a significantly better survival prognosis than patients in the high-risk group in both the training cohort (P < 0.0001) and the validation cohort (P = 0.0016).

Conclusion

We established and validated a novel nomogram model to predict the OS of SNMM patients stratified by age, T stage, N stage, surgery and radiotherapy. This predictive tool is of potential importance in the realms of patient counselling and clinical decision-making.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gilain L, Houette A, Montalban A, Mom T, Saroul N. Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):365–9.CrossRefPubMed Gilain L, Houette A, Montalban A, Mom T, Saroul N. Mucosal melanoma of the nasal cavity and paranasal sinuses. Eur Ann Otorhinolaryngol Head Neck Dis. 2014;131(6):365–9.CrossRefPubMed
2.
go back to reference Salari B, Foreman RK, Emerick KS, Lawrence DP, Duncan LM. Sinonasal mucosal melanoma: an update and review of the literature. Am J Dermatopathol. 2022;44(6):424–32.CrossRefPubMed Salari B, Foreman RK, Emerick KS, Lawrence DP, Duncan LM. Sinonasal mucosal melanoma: an update and review of the literature. Am J Dermatopathol. 2022;44(6):424–32.CrossRefPubMed
3.
go back to reference Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRefPubMed Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRefPubMed
4.
go back to reference Tian S, Li Q, Li R, Chen X, Tao Z, Gong H, et al. Development and validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma. Front Oncol. 2021;11:696952.CrossRefPubMedPubMedCentral Tian S, Li Q, Li R, Chen X, Tao Z, Gong H, et al. Development and validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma. Front Oncol. 2021;11:696952.CrossRefPubMedPubMedCentral
5.
go back to reference Ren C, Ma Y, Jin J, Ding J, Jiang Y, Wu Y, et al. Development and external validation of a dynamic nomogram to predict the survival for adenosquamous carcinoma of the pancreas. Front Oncol. 2022;12:927107.CrossRefPubMedPubMedCentral Ren C, Ma Y, Jin J, Ding J, Jiang Y, Wu Y, et al. Development and external validation of a dynamic nomogram to predict the survival for adenosquamous carcinoma of the pancreas. Front Oncol. 2022;12:927107.CrossRefPubMedPubMedCentral
6.
go back to reference Lombardi D, Bottazzoli M, Turri-Zanoni M, Raffetti E, Villaret AB, Morassi ML, et al. Sinonasal mucosal melanoma: a 12-year experience of 58 cases. Head Neck. 2016;38(Suppl 1):E1737–45.PubMed Lombardi D, Bottazzoli M, Turri-Zanoni M, Raffetti E, Villaret AB, Morassi ML, et al. Sinonasal mucosal melanoma: a 12-year experience of 58 cases. Head Neck. 2016;38(Suppl 1):E1737–45.PubMed
7.
go back to reference Dreno M, Georges M, Espitalier F, Ferron C, Charnole A, Dreno B, et al. Sinonasal mucosal melanoma: a 44-case study and literature analysis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):237–42.CrossRefPubMed Dreno M, Georges M, Espitalier F, Ferron C, Charnole A, Dreno B, et al. Sinonasal mucosal melanoma: a 44-case study and literature analysis. Eur Ann Otorhinolaryngol Head Neck Dis. 2017;134(4):237–42.CrossRefPubMed
8.
go back to reference Low CM, Price DL, Moore EJ, Stokken JK, Van Abel KM, Janus JR, et al. Nodal and distant metastases in sinonasal mucosal melanoma: a population-based analysis. Laryngoscope. 2020;130(3):622–7.CrossRefPubMed Low CM, Price DL, Moore EJ, Stokken JK, Van Abel KM, Janus JR, et al. Nodal and distant metastases in sinonasal mucosal melanoma: a population-based analysis. Laryngoscope. 2020;130(3):622–7.CrossRefPubMed
9.
go back to reference Konuthula N, Khan MN, Parasher A, Del Signore A, Genden EM, Govindaraj S, et al. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol. 2017;7(1):99–105.CrossRefPubMed Konuthula N, Khan MN, Parasher A, Del Signore A, Genden EM, Govindaraj S, et al. The presentation and outcomes of mucosal melanoma in 695 patients. Int Forum Allergy Rhinol. 2017;7(1):99–105.CrossRefPubMed
10.
11.
go back to reference Temmermand D, Kilic S, Mikhael M, Butler J, Unsal AA, Group E-W. Sinonasal mucosal melanoma: a Population-based comparison of the EUROCARE and SEER registries. Int Arch Otorhinolaryngol. 2022;26(3):e446–e52.CrossRefPubMedPubMedCentral Temmermand D, Kilic S, Mikhael M, Butler J, Unsal AA, Group E-W. Sinonasal mucosal melanoma: a Population-based comparison of the EUROCARE and SEER registries. Int Arch Otorhinolaryngol. 2022;26(3):e446–e52.CrossRefPubMedPubMedCentral
12.
go back to reference Lu Z, Zhou Y, Nie G, Miao B, Lu Y, Chen T. Prognostic Nomograms for Predicting overall survival and Cancer-specific survival in patients with Head and Neck Mucosal Melanoma. Int J Gen Med. 2022;15:2759–71.CrossRefPubMedPubMedCentral Lu Z, Zhou Y, Nie G, Miao B, Lu Y, Chen T. Prognostic Nomograms for Predicting overall survival and Cancer-specific survival in patients with Head and Neck Mucosal Melanoma. Int J Gen Med. 2022;15:2759–71.CrossRefPubMedPubMedCentral
13.
go back to reference Xu QQ, Li QJ, Chen L, Su XY, Song JX, Du J, et al. A nomogram for predicting survival of head and neck mucosal melanoma. Cancer Cell Int. 2021;21(1):224.CrossRefPubMedPubMedCentral Xu QQ, Li QJ, Chen L, Su XY, Song JX, Du J, et al. A nomogram for predicting survival of head and neck mucosal melanoma. Cancer Cell Int. 2021;21(1):224.CrossRefPubMedPubMedCentral
14.
go back to reference Zhu W, Zou B, Wang S. Clinicopathological features and prognosis of Sinonasal Mucosal malignant melanoma: a retrospective study of 83 cases in a Chinese Population. ORL J Otorhinolaryngol Relat Spec. 2016;78(2):94–104.CrossRefPubMed Zhu W, Zou B, Wang S. Clinicopathological features and prognosis of Sinonasal Mucosal malignant melanoma: a retrospective study of 83 cases in a Chinese Population. ORL J Otorhinolaryngol Relat Spec. 2016;78(2):94–104.CrossRefPubMed
15.
go back to reference Ganti A, Raman A, Shay A, Kuhar HN, Auger SR, Patel T, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2020;130(2):275–82.CrossRefPubMed Ganti A, Raman A, Shay A, Kuhar HN, Auger SR, Patel T, et al. Treatment modalities in sinonasal mucosal melanoma: a national cancer database analysis. Laryngoscope. 2020;130(2):275–82.CrossRefPubMed
16.
go back to reference Lundberg M, Haapaniemi A, Hagstrom J, Juteau S, Hernberg M, Makitie AA, et al. Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma. Rhinology. 2019;57(2):132–8.PubMed Lundberg M, Haapaniemi A, Hagstrom J, Juteau S, Hernberg M, Makitie AA, et al. Similar survival outcome after endoscopic and open approaches for sinonasal mucosal melanoma. Rhinology. 2019;57(2):132–8.PubMed
17.
go back to reference Schmidt MQ, David J, Yoshida EJ, Scher K, Mita A, Shiao SL, et al. Predictors of survival in head and neck mucosal melanoma. Oral Oncol. 2017;73:36–42.CrossRefPubMed Schmidt MQ, David J, Yoshida EJ, Scher K, Mita A, Shiao SL, et al. Predictors of survival in head and neck mucosal melanoma. Oral Oncol. 2017;73:36–42.CrossRefPubMed
18.
go back to reference Khan MN, Kanumuri VV, Raikundalia MD, Vazquez A, Govindaraj S, Baredes S, et al. Sinonasal melanoma: survival and prognostic implications based on site of involvement. Int Forum Allergy Rhinol. 2014;4(2):151–5.CrossRefPubMed Khan MN, Kanumuri VV, Raikundalia MD, Vazquez A, Govindaraj S, Baredes S, et al. Sinonasal melanoma: survival and prognostic implications based on site of involvement. Int Forum Allergy Rhinol. 2014;4(2):151–5.CrossRefPubMed
19.
go back to reference Swegal W, Koyfman S, Scharpf J, Sindwani R, Greskovich J, Borden E, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014;140(9):840–5.CrossRefPubMed Swegal W, Koyfman S, Scharpf J, Sindwani R, Greskovich J, Borden E, et al. Endoscopic and open surgical approaches to locally advanced sinonasal melanoma: comparing the therapeutic benefits. JAMA Otolaryngol Head Neck Surg. 2014;140(9):840–5.CrossRefPubMed
20.
go back to reference Hu R, Yang BB. Surgery alone versus post-operative radiotherapy for sinonasal malignant melanoma: a meta-analysis. J Laryngol Otol. 2018;132(12):1051–60.CrossRefPubMed Hu R, Yang BB. Surgery alone versus post-operative radiotherapy for sinonasal malignant melanoma: a meta-analysis. J Laryngol Otol. 2018;132(12):1051–60.CrossRefPubMed
21.
go back to reference Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, et al. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol. 2017;112:136–52.CrossRefPubMed Ascierto PA, Accorona R, Botti G, Farina D, Fossati P, Gatta G, et al. Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol. 2017;112:136–52.CrossRefPubMed
22.
go back to reference Xu QQ, Lai YZ, Huang ZL, Zeng ZY, Zhang YN, Ou RY, et al. Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities. Radiat Oncol. 2021;16(1):138.CrossRefPubMedPubMedCentral Xu QQ, Lai YZ, Huang ZL, Zeng ZY, Zhang YN, Ou RY, et al. Clinical outcomes and patterns of failure of head and neck mucosal melanoma treated with multiple treatment modalities. Radiat Oncol. 2021;16(1):138.CrossRefPubMedPubMedCentral
23.
go back to reference Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, et al. Noncutaneous melanomas: a single-center analysis. Dermatology. 2016;232(1):22–9.CrossRefPubMed Del Prete V, Chaloupka K, Holzmann D, Fink D, Levesque M, Dummer R, et al. Noncutaneous melanomas: a single-center analysis. Dermatology. 2016;232(1):22–9.CrossRefPubMed
24.
go back to reference D’Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of Nivolumab alone or in Combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226–35.CrossRefPubMed D’Angelo SP, Larkin J, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of Nivolumab alone or in Combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35(2):226–35.CrossRefPubMed
25.
go back to reference Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer. 2013;109(3):559–64.CrossRefPubMedPubMedCentral Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. Br J Cancer. 2013;109(3):559–64.CrossRefPubMedPubMedCentral
26.
go back to reference Amit M, Tam S, Abdelmeguid AS, Roberts DB, Takahashi Y, Raza SM, et al. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017;116(12):1564–71.CrossRefPubMedPubMedCentral Amit M, Tam S, Abdelmeguid AS, Roberts DB, Takahashi Y, Raza SM, et al. Mutation status among patients with sinonasal mucosal melanoma and its impact on survival. Br J Cancer. 2017;116(12):1564–71.CrossRefPubMedPubMedCentral
27.
go back to reference Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, Andre J, Dumaz N, et al. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol. 2013;44(9):1902–11.CrossRefPubMedPubMedCentral Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, Andre J, Dumaz N, et al. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations. Hum Pathol. 2013;44(9):1902–11.CrossRefPubMedPubMedCentral
28.
go back to reference Rapisuwon S, Parks K, Al-Refaie W, Atkins MB. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma Res. 2014;24(5):509–11.CrossRefPubMed Rapisuwon S, Parks K, Al-Refaie W, Atkins MB. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report. Melanoma Res. 2014;24(5):509–11.CrossRefPubMed
29.
go back to reference Cao J, Yu Y, Zhou Y, Ji Q, Qian W, Jia D, et al. Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma. Front Oncol. 2022;12:942258.CrossRefPubMedPubMedCentral Cao J, Yu Y, Zhou Y, Ji Q, Qian W, Jia D, et al. Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma. Front Oncol. 2022;12:942258.CrossRefPubMedPubMedCentral
30.
go back to reference Guo R, Jenkins SM, Johnson BJ, Reed K, Kroneman T, Choby G. Sinonasal mucosal melanoma: role of Tumor proliferative indices and pathological factors in Survival. Laryngoscope. 2022;132(12):2350–8.CrossRefPubMed Guo R, Jenkins SM, Johnson BJ, Reed K, Kroneman T, Choby G. Sinonasal mucosal melanoma: role of Tumor proliferative indices and pathological factors in Survival. Laryngoscope. 2022;132(12):2350–8.CrossRefPubMed
31.
go back to reference Liu HQ, Zou BQ, Wang SY. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma]. Zhonghua Bing Li Xue Za Zhi. 2017;46(11):782–8.PubMed Liu HQ, Zou BQ, Wang SY. [Expression and prognostic values of PD-1, PD-L1 and IDO-1 in sinonasal malignant mucosal melanoma]. Zhonghua Bing Li Xue Za Zhi. 2017;46(11):782–8.PubMed
Metadata
Title
Development and validation of a nomogram for predicting overall survival in patients with sinonasal mucosal melanoma
Authors
Zhenzhen Zhu
Weiqing Wang
Yang Zha
Xiaowei Wang
Surita Aodeng
Lei Wang
Yuzhuo Liu
Wei Lv
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11888-5

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine